Obstructive Sleep Apnea (OSA): Snoring, Daytime Sleepiness, and CPAP Therapy

Obstructive Sleep Apnea (OSA) is a prevalent sleep-related breathing disorder characterized by repetitive episodes of partial (hypopnea) or complete (apnea) collapse of the upper airway during sleep. These episodes lead to transient arterial oxygen desaturation, carbon dioxide retention, and autonomic arousal, resulting in sleep fragmentation. OSA is associated with significant cardiovascular, metabolic, and neurocognitive complications, making early screening, diagnosis, and treatment essential.

Pathophysiology of Upper Airway Collapse

The airway collapse in OSA occurs during sleep due to the loss of neuromuscular tone in the pharyngeal dilator muscles (primarily the genioglossus muscle) combined with anatomical factors that narrow the pharyngeal lumen. Anatomical risk factors include obesity (causing fat deposition in the lateral pharyngeal walls), micrognathia, retrognathia, tonsillar hypertrophy, and a macroglossia. During sleep, particularly during Rapid Eye Movement (REM) sleep when muscle hypotonia is pronounced, these factors lead to airway collapse. The resulting airway obstruction prevents air from entering the lungs despite continued thoracic and abdominal respiratory efforts. This causes hypoxemia and hypercapnia, which stimulate peripheral and central chemoreceptors, triggering a sympathetic surge that wakes the patient to restore airway patency. These micro-arousals disrupt sleep architecture, preventing restorative deep sleep.

OSA can also coexist with chronic airway diseases, a clinical presentation known as overlap syndrome; patients with underlying respiratory distress should review guidelines in COPD Management to evaluate their respiratory status.

Clinical Symptoms and Signs

The clinical presentation of OSA includes nocturnal and daytime symptoms:

• Nocturnal Symptoms: Loud, habitual snoring is the most common symptom, often punctuated by witnessed apneas, gasping, or choking episodes. Nocturnal diaphoresis, frequent nocturia (caused by elevated atrial natriuretic peptide from increased negative intrathoracic pressure), and sleep disruption are also common.
• Daytime Symptoms: Excessive daytime sleepiness (EDS) is the hallmark symptom, often assessed using the Epworth Sleepiness Scale (ESS). Patients also report morning headaches (caused by nocturnal hypercapnia-induced cerebral vasodilation), difficulty concentrating, irritability, and depressive symptoms.

Screening and Diagnostic Evaluation

Initial clinical screening is performed using validated questionnaires. The gold standard for diagnosing OSA is in-laboratory Polysomnography (PSG), which monitors electroencephalography (EEG), electrooculography (EOG), electromyography (EMG), electrocardiography (ECG), nasal airflow, thoracic and abdominal effort, and oxygen saturation. For patients without significant comorbidities (such as heart failure or neuromuscular disease), Home Sleep Apnea Testing (HSAT) can be performed. The severity of OSA is determined using the Apnea-Hypopnea Index (AHI):

• Mild OSA: AHI of 5 to 14.9 events per hour of sleep.
• Moderate OSA: AHI of 15 to 29.9 events per hour of sleep.
• Severe OSA: AHI of ≥ 30 events per hour of sleep.

💡 💡 STOP-BANG Screening Tool

The STOP-BANG questionnaire is a validated screening tool for OSA. Scoring is based on: Snoring loudly; Tiredness during the day; Observed apneas; high Blood pressure; Body Mass Index > 35 kg/m²; Age > 50 years; Neck circumference > 17 inches (men) or > 16 inches (women); Male Gender. A score of ≥ 3 indicates moderate-to-high risk, and ≥ 5 indicates high risk of moderate-to-severe OSA.

Cardiovascular and Systemic Complications

Untreated OSA is a major risk factor for several cardiovascular and metabolic disorders. The repetitive sympathetic surges and systemic inflammation caused by intermittent hypoxemia contribute to:

1. Cardiovascular Disease: Resistant hypertension, coronary artery disease, myocardial infarction, congestive heart failure, and stroke.
2. Arrhythmias: Ocular and systemic hypoxemia is linked to a higher incidence of cardiac arrhythmias, particularly atrial fibrillation.
3. Metabolic Dysregulation: Insulin resistance, type 2 diabetes mellitus, and metabolic syndrome.

Evidence-Based Management

Treatment is tailored to the severity of OSA and patient preference:

• Continuous Positive Airway Pressure (CPAP): The gold standard therapy for moderate-to-severe OSA. CPAP acts as a pneumatic splint, delivering a continuous stream of pressurized air that keeps the upper airway open. Patient compliance can be optimized through mask fitting, heated humidification, and ramp-up pressure settings.
• Oral Appliances: Mandibular Advancement Devices (MADs) hold the jaw and tongue forward, opening the airway. They are indicated for patients with mild-to-moderate OSA or those who cannot tolerate CPAP.
• Lifestyle Modifications: Weight loss (which reduces pharyngeal fat deposition), avoiding alcohol and sedatives before bedtime (as they reduce upper airway muscle tone), and positional therapy (sleeping in a non-supine position).
• Surgical Options: Uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement, or hypoglossal nerve stimulation for selected patients.

💡 Frequently Asked Questions (FAQ)

📚 References & Sources

1. Kapur, V. K., et al. (2017). Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine, 13(3), 479-504.
2. Patil, S. P., et al. (2019). Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine, 15(2), 335-343.
3. Peppard, P. E., et al. (2013). Increased prevalence of sleep-disordered breathing in adults. American Journal of Epidemiology, 177(9), 1006-1014.